The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and AGC Biologics, your friendly CDMO expert, have signed a licensing agreement for Asimov’s off-the-shelf ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

CINCINNATI & COLUMBUS, Ohio--(BUSINESS WIRE)--Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy ...

Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...

Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...